Form 4: Enliven Therapeutics CFO Sells Shares
Insider Transaction (Form 4)
Benjamin Hohl, CHIEF FINANCIAL OFFICER of Enliven Therapeutics, Inc., sold 6,018 shares of common stock on September 17, 2026.
Summary
- Option exercise/conversion: acquired 3,982 Common Stock at $14.85 ($59,133) on September 17, 2026; holds 44,018 after (Direct).
- Open-market sale: disposed of 3,535 Common Stock at $50.03 ($176,851) on September 17, 2026; holds 40,483 after (Direct).
- Open-market sale: disposed of 2,194 Common Stock at $50.72 ($111,270) on September 17, 2026; holds 38,289 after (Direct).
- Open-market sale: disposed of 289 Common Stock at $51.49 ($14,881) on September 17, 2026; holds 38,000 after (Direct).
- Option exercise/conversion: disposed of 3,982 Stock Option (right to buy) on September 17, 2026; holds 181,018 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $303,003 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Benjamin Hohl — Officer (CHIEF FINANCIAL OFFICER)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-17 | Option exercise/conversion | Common Stock | 3,982 | $15 | $59.1K | 44,018 |
| 2026-09-17 | Open-market sale | Common Stock | 3,535 | $50 | $176.9K | 40,483 |
| 2026-09-17 | Open-market sale | Common Stock | 2,194 | $51 | $111.3K | 38,289 |
| 2026-09-17 | Open-market sale | Common Stock | 289 | $51 | $14.9K | 38,000 |
| 2026-09-17 | Option exercise/conversion | Stock Option (right to buy) | 3,982 | — | — | 181,018 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-17 | Option exercise/conversion (3,982 shares) |
| 2026-09-17 | Open-market sale (3,535 shares) |
| 2026-09-17 | Open-market sale (2,194 shares) |
| 2026-09-17 | Open-market sale (289 shares) |
| 2026-09-17 | Option exercise/conversion (3,982 shares) |
Keywords
insider transaction, Form 4, ELVN, Enliven Therapeutics, Inc., bearish, Benjamin Hohl
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.